Investor Relations

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/16/17KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa, Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported the successful completion of an End-of-Phase 2 (EOP2) meeting with the FDA for KP415, the company’s extended release ... 
Printer Friendly Version
11/09/17KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA; Cleared to Proceed to Clinical Studies Announced FDRR Process Completion and Resubmission of the Apadaz™ NDA --  FDA Has Assigned a PDUFA Action Date of February 23, 2018 Entered into Licensing and Assignment Ag... 
Printer Friendly Version
11/06/17KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse CORALVILLE, Iowa, Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc, a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the United States Adopted Name (USAN) Council approved the use of the nonproprietary name, "Asalhydromorphone (As... 
Printer Friendly Version
11/02/17KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies
KP484 Designed to be a Predictably Dosed, “Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa, Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc, a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) has completed its safety review of the Investigational New Drug (IND) application for KP484, the Company’s prodrug product candidate of “super-ex... 
Printer Friendly Version
11/01/17KemPharm, Inc. to Report Third Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  November 9, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, November 9, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the th... 
Printer Friendly Version
10/04/17KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa, Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that it has entered into a technology licensing and assignment agreement with Genco Sciences, LLC (Genco).  Utilizing Genco’s early research-stage proprietary na... 
Printer Friendly Version
09/20/17KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin human clinical trials of KP484, the Company’s prodrug product candi... 
Printer Friendly Version
09/12/17KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa, Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced completion of the Formal Dispute Resolution Request (FDRR) process with the U.S. Food and Drug Administration (FDA) for Apadaz™ (benzhydrocodone and acetaminoph... 
Printer Friendly Version
08/31/17KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
CORALVILLE, Iowa, Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  announced today that its President and Chief Executive Officer, Travis C. Mickle, Ph.D., will present at the the Rodman & Renshaw 19th Annual Global Investment Conference being held September 10-12, 2017, at the Lotte New York Palace in New York City. Details of KemPharm's presentation are a... 
Printer Friendly Version
08/10/17KemPharm, Inc. Reports Second Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights: KP415.109 Pharmacokinetics Phase 1 Trial Completed Held KP415 End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) Initiated Development of KP484, A Super-Extended Release Attention-Deficit/Hyperactivity Disorder (ADHD) Methylphenidate Product Candidate Presented Clinical Data for KP511 at the International Conference... 
Printer Friendly Version
08/10/17KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa, Aug. 10, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced preliminary results of KP415.109, a Phase I trial designed to assess the relative pharmacokinetics (PK) of three different formulatio... 
Printer Friendly Version
08/08/17KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety
Study Confirms Intranasal Abuse of Hydrocodone/Acetaminophen by Adolescents & Adults may be a Significant Public Health Issue CORALVILLE, Iowa, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the publication of the results from a study conducted by Inflexxion, Inc. evaluating the patterns of abuse and how immediate-release hydrocodone acetam... 
Printer Friendly Version
08/03/17KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference
CORALVILLE, Iowa, Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference being held August 9-10, 2017, at the InterContinental Boston Hotel. Details of KemPharm's presentation are as follows: Date:  ... 
Printer Friendly Version
08/01/17KemPharm, Inc. to Report Second Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for August 10, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Aug. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, August 10, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the secon... 
Printer Friendly Version
06/28/17KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate
KP415 End-of-Phase 1 Meeting with FDA Affirms KemPharm’s Development Plan and Potential NDA Submission as early as late 2018 Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET CORALVILLE, Iowa, June 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced two significant advances involving its prodrug developme... 
Printer Friendly Version
06/26/17KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone
US Patent and Trademark Office issues patent protection to KP746, an investigational therapy for the treatment of pain with a prodrug of oxymorphone CORALVILLE, Iowa, June 26, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced a further enhancement to KemPharm's U.S. and global intellectual property estate governing its portfolio of prodrug product candidat... 
Printer Friendly Version
06/09/17KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids
Poster Presentation Highlights Intranasal Abuse Deterrence Technology CORALVILLE, Iowa, June 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, will present clinical data for its opioid prodrug product candidate, KP511, KemPharm’s prodrug of hydromorphone, at the International Conference on Opioids (ICOO) Annual Meeting, to be held June 11-14, 2017. “We believe the ... 
Printer Friendly Version
06/01/17KemPharm Announces Addition to Leadership Team
Andrew Barrett, Ph.D., appointed Vice President, Scientific Affairs CORALVILLE, Iowa, June 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an addition to its senior leadership team with the promotion of Dr. Andrew Barrett as Vice President, Scientific Affairs.  Dr. Barrett has contributed to KemPharm’s scientific research and development since early ... 
Printer Friendly Version
05/10/17KemPharm, Inc. Reports First Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights: Reported Positive Data from Proof-of-Concept Phase 1 Intranasal Pharmacokinetic Study of KP511 Announced Additional U.S. Patents for KP511 and KP201/IR Presented Clinical Data for KP201/IR and KP511 at American Academy of Pain Medicine’s Annual Meeting Financial Highlights: Net loss of $0.84 per basic and diluted share for the ... 
Printer Friendly Version
05/01/17KemPharm, Inc. to Report First Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2017, 4:30 p.m. ET CORALVILLE, Iowa, May 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quart... 
Printer Friendly Version
03/27/17KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum
CORALVILLE, Iowa, March 27, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that Andrew Barrett, Ph.D., Senior Director, Scientific Affairs, will present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum being held March 27, 2017, at the New York Academy of Sciences. Details of KemPharm's presentation are as follows: ... 
Printer Friendly Version
03/16/17KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
Poster Presentations Highlight Oral Equivalency and Intranasal Abuse Deterrence Technology CORALVILLE, Iowa, March 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, presented clinical data from two of its opioid prodrug candidates, KP511, KemPharm’s prodrug of hydromorphone, and KP201/IR, KemPharm’s prodrug of hydrocodone, at the American Academy of Pain Medicine (AAPM)... 
Printer Friendly Version
03/09/17KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights: Reported Positive Data from Phase 1 Proof-of-Concept Clinical Trial of KP415 Received Clearance from FDA to Initiate Clinical Program for KP201/IR Granted “Fast Track” Designation from FDA for KP201/IR Reported Positive Data from Proof-of-Concept Phase 1 Intranasal Pharmacokinetic Study of KP511 Recent Corporate and Financ... 
Printer Friendly Version
02/28/17KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  March 9th, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth... 
Printer Friendly Version
02/23/17KemPharm Announces Additional Patent Protection for Prodrug Portfolio
US Patent and Trademark Office decision extends additional patent protection to KP201 and the KP511 compound family CORALVILLE, Iowa, Feb. 23, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced enhancements to its U.S. and global intellectual property estate governing its portfolio of prodrug product candidates.  The United States Patent and Trademark Offic... 
Printer Friendly Version
02/07/17KemPharm to Present at Upcoming Investor Conferences
Management Presentations to Focus on Depth of Product Pipeline CORALVILLE, Iowa, Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March. Details of KemPharm's presentations are as follows: Even... 
Printer Friendly Version
01/09/17KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain
Statistically significant pharmacokinetic and pharmacodynamic differences of abuse potential were observed in the KP511.A01 Study CORALVILLE, Iowa, Jan. 09, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the results of its exploratory Phase 1, double-blind, single-dose, 2-treatment, 2-period, randomized, crossover study (Study KP511.A01) intended to ass... 
Printer Friendly Version
01/04/17KemPharm to Present at Biotech Showcase 2017
CORALVILLE, Iowa, Jan. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its President and Chief Executive Officer, Travis Mickle, Ph.D., will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square. Details of KemPharm's presentation are as follows: Event:   Biotech Showcase 20... 
Printer Friendly Version